Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2018 | KRd improves response rates vs. VRd in newly diagnosed myeloma

Ola Landgren • 3 Dec 2018
ASH 2018
Multiple Myeloma Bortezomib Carfilzomib Dexamethasone Lenalidomide
CoMMpass

Triplet regimens containing a proteasome inhibitor and immunomodulatory agent are the standard of care for newly diagnosed multiple myeloma (NDMM). Here, Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, NY, discusses the results of the CoMMpass study (NCT01454297), which investigated carfilzomib-lenalidomide-dexamethasone (KRd) vs. bortezomib-lenalidomide-dexamethasone (VRd) in NDMM. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Ola Landgren

Trends in the evolving myeloma treatment landscape: observations from ASCO 2025 3:42
Trends in the evolving myeloma treatment landscape: observations from ASCO 2025
Ola Landgren • 6 Jun 2025
An update on the ADVANCE trial comparing Dara-KRd versus KRd in newly diagnosed myeloma 3:38
An update on the ADVANCE trial comparing Dara-KRd versus KRd in newly diagnosed myeloma
Ola Landgren • 6 Jun 2025
Where is the smoldering myeloma field moving, and what does future management look like? 4:02
Where is the smoldering myeloma field moving, and what does future management look like?
Ola Landgren • 6 Jun 2025
MRD as an early endpoint for accelerated approval in myeloma: current perspectives & future outlooks 5:32
MRD as an early endpoint for accelerated approval in myeloma: current perspectives & future outlooks
Dickran Kazandjian et al. • 11 Apr 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals